Innodata Beats Q3 Estimates, Yet Valuation and Concentration Risks Keep Rating at WAIT

What happened

Innodata reported Q3 2026 earnings of $0.29 per share, exceeding the Zacks Consensus Estimate of $0.21, while revenue also topped expectations. Year-over-year, EPS improved from $0.24, indicating continued profitability growth amid robust AI data service demand. This beat aligns with the company's recent trajectory of strong execution, as seen in Q1 2026 revenue growth of 54% YoY and raised FY2026 guidance to ~40% or more. However, the result does not address the dominant concern in our analysis: extreme customer concentration, with one customer accounting for ~56% of revenue and ~65% of accounts receivable as of Q1 2026. The stock's premium valuation (P/E ~74, EV/EBITDA ~59) remains vulnerable to any project reductions or contract cancellations, and the positive earnings surprise alone does not justify an upgrade from WAIT.

Implication

Investors should treat this beat as a positive data point but not as a signal to chase the stock, given that the valuation already embeds high growth expectations. The next critical disclosures will be the quarterly 10-Q, particularly customer concentration metrics and any updates on the ramp of the second large customer targeted to reach ~$51M annual revenue. Maintenance of the ~40%+ FY2026 revenue growth guidance and gross margins near 42-44% will be essential to support the current price. Any signs of contract volume reductions or delays from the top customer would likely trigger a sharp de-rating, as the business remains project-based and at-will. Therefore, existing holders should use strength to reassess position sizing, while new investors may wait for a better entry near $70 or clear evidence of customer diversification before committing capital.

Thesis delta

The Q3 earnings beat reinforces the near-term growth narrative and is consistent with the bull case scenario, but it does not alter the fundamental risk profile. Customer concentration and contract visibility concerns remain unresolved, so the WAIT rating and $95 base-case implied value stay unchanged. The report will need to show progress on diversification in subsequent quarters to warrant a more positive stance.